Autologe hämatopoetische Stammzelltransplantation bei systemischer Sklerose
Standard
Autologe hämatopoetische Stammzelltransplantation bei systemischer Sklerose : Positionspapier des Arbeitskreises Stammzelltherapie der Deutschen Gesellschaft für Rheumatologie. / Alexander, T; Henes, J; Distler, J H W; Schmalzing, M; Blank, N; Kötter, I; Hiepe, F.
in: Z RHEUMATOL, Jahrgang 79, Nr. 5, 06.2020, S. 429-436.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Autologe hämatopoetische Stammzelltransplantation bei systemischer Sklerose
T2 - Positionspapier des Arbeitskreises Stammzelltherapie der Deutschen Gesellschaft für Rheumatologie
AU - Alexander, T
AU - Henes, J
AU - Distler, J H W
AU - Schmalzing, M
AU - Blank, N
AU - Kötter, I
AU - Hiepe, F
PY - 2020/6
Y1 - 2020/6
N2 - There have been three randomized controlled trials on autologous hematopoietic stem cell transplantation (AHSCT) in systemic sclerosis (SSc) that demonstrated significant superiority with respect to survival, improvement of cutaneous fibrosis, lung function and quality of life compared to standard treatment; however, these advantages must be carefully weighed against the transplantation-related risks. For this reason, an expert group from the stem cell therapy working party of the German Society for Rheumatology (DGRh) has now developed recommendations for the use of AHSCT in SSc. Based on the high-quality evidence, AHSCT is considered as the standard option for the treatment of selected SSc patients. Potential candidates for AHSCT are those with early, rapidly progressive, diffuse cutaneous SSc with visceral manifestations who have not yet developed severe damage to internal organs. A close cooperation between rheumatologists and transplantation centers is crucial for optimizing patient selection and treatment outcomes.
AB - There have been three randomized controlled trials on autologous hematopoietic stem cell transplantation (AHSCT) in systemic sclerosis (SSc) that demonstrated significant superiority with respect to survival, improvement of cutaneous fibrosis, lung function and quality of life compared to standard treatment; however, these advantages must be carefully weighed against the transplantation-related risks. For this reason, an expert group from the stem cell therapy working party of the German Society for Rheumatology (DGRh) has now developed recommendations for the use of AHSCT in SSc. Based on the high-quality evidence, AHSCT is considered as the standard option for the treatment of selected SSc patients. Potential candidates for AHSCT are those with early, rapidly progressive, diffuse cutaneous SSc with visceral manifestations who have not yet developed severe damage to internal organs. A close cooperation between rheumatologists and transplantation centers is crucial for optimizing patient selection and treatment outcomes.
KW - Germany
KW - Hematopoietic Stem Cell Transplantation
KW - Humans
KW - Quality of Life
KW - Rheumatology/standards
KW - Scleroderma, Systemic/therapy
KW - Transplantation, Autologous
U2 - 10.1007/s00393-020-00789-0
DO - 10.1007/s00393-020-00789-0
M3 - SCORING: Review
C2 - 32322977
VL - 79
SP - 429
EP - 436
JO - Z RHEUMATOL
JF - Z RHEUMATOL
SN - 0340-1855
IS - 5
ER -
